Bosutinib 400 MG Oral Tablet [Bosulif] — RxCUI 1987734
RxNorm drug concept · Semantic branded drug
RxCUI 1987734
Semantic branded drug · SBD
● Current RxNorm concept 6 FDA products
6 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1987734
Official nameBosutinib 400 MG Oral Tablet [Bosulif]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asBosulif 400 MG Oral Tablet; Bosulif 400 MG (as bosutinib monohydrate 413.6 MG) Oral Tablet
FDA products mapped6
Package NDCs mapped6
Reported Medicaid activity (SDUD)1,739 prescriptions · 20 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Bosutinib: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- You have a type of leukemia called Ph+ CML, which is driven by a faulty protein in your blood cells called BCR-ABL. Think of it like a stuck 'on' switch that keeps telling those ce...
- What exactly is bosutinib treating in my body?
- Yes — this is actually pretty important. Food significantly increases how much of the medicine your body absorbs, so taking it on an empty stomach means you'd be getting much less...
- Do I have to take it with food every single time?
🕸️ Concept Web — How Bosutinib 400 MG Oral Tablet [Bosulif] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Bosutinib 400 MG Oral Tablet [Bosulif]
RxCUI 1987734 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Bosutinib
1307619IN
-
Bosutinib
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Bosulif
1307625BN
-
Bosulif
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Bosutinib Oral Tablet
1307623SCDF -
Bosutinib Oral Product
1307621SCDG -
Bosutinib Pill
1307622SCDG -
Bosutinib Oral Tablet [Bosulif]
1307627SBDF -
Bosulif Oral Product
1307628SBDG -
Bosulif Pill
1307629SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Bosutinib Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Bosutinib 400 MG Oral Tablet
1987732SCD -
Bosutinib 400 MG
1988983SCDC -
Bosutinib 400 MG [Bosulif]
1988985SBDC
-
Bosutinib 400 MG Oral Tablet
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Bosutinib 400 MG Oral Tablet
SCD · 1987732 -
Bosutinib 400 MG
SCDC · 1988983 -
Bosutinib Oral Tablet
SCDF · 1307623 -
Bosutinib Oral Product
SCDG · 1307621 -
Bosutinib Pill
SCDG · 1307622
Brand-Name Concepts
-
Bosutinib 400 MG [Bosulif]
SBDC · 1988985 -
Bosutinib Oral Tablet [Bosulif]
SBDF · 1307627 -
Bosulif Oral Product
SBDG · 1307628 -
Bosulif Pill
SBDG · 1307629 -
Bosulif
BN · 1307625
📦 FDA Products & Package NDCs
6 products · 6 package NDCs
6 package NDCs map to RxCUI 1987734 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00069-0135-01 | 120 TABLET, FILM COATED in 1 BOTTLE (0069-0135-01) | BOSULIF | Pfizer Laboratories Div Pfizer Inc | 2012-09-04 |
| 00069-0136-01 | 30 TABLET, FILM COATED in 1 BOTTLE (0069-0136-01) | BOSULIF | Pfizer Laboratories Div Pfizer Inc | 2012-09-04 |
| 00069-0193-01 | 30 TABLET, FILM COATED in 1 BOTTLE (0069-0193-01) | BOSULIF | Pfizer Laboratories Div Pfizer Inc | 2017-12-18 |
| 00069-0504-30 | 30 CAPSULE in 1 BOTTLE (0069-0504-30) | BOSULIF | Pfizer Laboratories Div Pfizer Inc | 2024-01-02 |
| 00069-1014-15 | 150 CAPSULE in 1 BOTTLE (0069-1014-15) | BOSULIF | Pfizer Laboratories Div Pfizer Inc | 2024-01-02 |
| 63539-0193-30 | 30 TABLET, FILM COATED in 1 BOTTLE (63539-193-30) | BOSULIF | U.S. Pharmaceuticals | 2018-02-21 |
Observed labelers:
Pfizer Laboratories Div Pfizer Inc (5) ·
U.S. Pharmaceuticals (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.